Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
34 hedge funds and large institutions have $69.9M invested in Trillium Therapeutics Inc. in 2015 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 1 closing their positions.
2,000% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 1
267% more capital invested
Capital invested by funds: $19M → $69.9M (+$50.9M)
143% more funds holding
Funds holding: 14 → 34 (+20)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$9.59M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$9.01M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$8.54M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$6.84M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$1.51M |
| 2 |
DM
Deerfield Management
New York
|
-$1.23M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$506K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$228K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$20.5K |
TRIL Hedge Fund Activity: Q2 2015 in Review
34 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2015, worth a combined $69.9M — up 267% from $19M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TRIL positions and 1 closed out — a net gain of 20 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Private Capital Advisors, adding an estimated $9.59M. The largest seller was Avoro Capital Advisors, cutting an estimated $1.51M.
- 34 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2015, up from 14 in Q1 2015.
- Funds reported $69.9M of Trillium Therapeutics Inc. stock for Q2 2015, up 267% quarter-over-quarter.
- 21 funds opened new Trillium Therapeutics Inc. positions in Q2 2015 and 1 closed out, a net change of +20 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2015 was Private Capital Advisors, an estimated $9.59M added.
- The largest Trillium Therapeutics Inc. seller in Q2 2015 was Avoro Capital Advisors, an estimated $1.51M sold.
Based on aggregated 13F filings for Q2 2015.